Search results for the keyword {phrase} ({results_count} of {results_count_total}). There will be further results within Author, Category and Institution pages directly.
Displaying {results_count} results of {results_count_total}
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
Talazoparib plus enzalutamide showed improved radiographic progression-free survival (rPFS) compared to placebo plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
The most common treatment-emergent adverse events observed in the talazoparib group were anaemia, neutropenia, and fatigue, with anaemia being the most common grade 3-4 event.
Faculti is a research, policy and scholarship streaming platform, set up by a former school teacher, that covers 8000 academics annually across 20 subjects, across the world. The aim is to interview academics and policy makers discussing their research or analysis without any journalistic influence or bias. More here
How do you select interviews?
Team of editors across all the main disciplines select publications along a three-pronged approach: 1. Most cited and latest in each subject 2. Internal audience website data 3. Publisher Partners suggestions eg Taylor and Francis, Princeton University Press, they suggest what to cover.
Interview Process
All questions sent in advance by 4-5 days. Interview undertaken on Zoom, Webex or phone. Journalist checks for framing, lighting, sound. Journalist interviews you, asks follow-ups, retakes. Raw footage enters editing cycle.